Tissue-agnostic minimal residual disease (MRD) solution unbounded to baseline samples

• Universal MRD solution unbounded to baseline sample availability 

• MRD detection with ability to capture new actionable mutations undetected at baseline

• Designed to monitor cancer treatment response or detect cancer recurrence

• Adopted by leading biopharmas in global clinical trials


Features and benefits

Low Input of Predicine Assays

MRD detection unbounded by baseline sample

High Sensitivity Predicine

Ultra sensitivity 0.005% VAF LOD

Actionable molecular insights

CLIA Validated ATLAS

Plasma, urine, or tissue acceptable for baseline profiling

Sample types

Whole blood

Sample requirements

30-60 ng of cfDNA

Turnaround time

10 days


Technical specifications

Seeing the unseen: Ultra deep next generation sequencing

PredicineALERT™ helps you detect novel acquired alterations that are missed from other MRD tests.  Plasma-level VAF limit of detection (LOD) for conventional technologies are at 0.01%, which is 2X lower than the 0.005% VAF LOD achieved with PredicineALERT™. 

MRD detection unbounded by baseline samples

MRD detection with PredicineALERT™ is different from conventional MRD assays because it is not limited to baseline samples.  If available, baseline can be assessed using patient’s plasma, urine or tissue. If baseline sample is unavailable, monitoring the recurrence or progression of cancer can be achieved with a simple blood draw with our tissue-agnostic approach.  


We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.